HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masahiro Natsuaki Selected Research

Acute Coronary Syndrome

5/2024An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
1/2024Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial.
11/2023An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.
11/2023Statin Discontinuation After Coronary Revascularization.
8/2023Single-Session Versus Staged Multivessel Optimal IVUS-Guided PCI in Patients With CCS or NSTE-ACS.
1/2023Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome　- A Post Hoc Secondary Analysis of STOPDAPT-2 ACS.
1/2023Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.
1/2022Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
1/2022Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
10/2021Effects of Acute Coronary Syndrome and Stable Coronary Artery Disease on Bleeding and Ischemic Risk After Percutaneous Coronary Intervention.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masahiro Natsuaki Research Topics

Disease

43Myocardial Infarction
05/2024 - 02/2010
39Thrombosis (Thrombus)
05/2024 - 09/2012
39Hemorrhage
05/2024 - 05/2012
23Stroke (Strokes)
11/2023 - 01/2011
13Coronary Artery Disease (Coronary Atherosclerosis)
11/2023 - 06/2012
12Acute Coronary Syndrome
05/2024 - 01/2020
6Ischemic Stroke
05/2024 - 01/2018
5ST Elevation Myocardial Infarction
01/2024 - 04/2013
3Neoplasms (Cancer)
11/2023 - 01/2022
3Chronic Renal Insufficiency
02/2023 - 12/2012
3Atrial Fibrillation
01/2020 - 07/2014
3Death (Near-Death Experience)
01/2018 - 09/2013
2Body Weight (Weight, Body)
01/2022 - 01/2020
2Ischemia
01/2020 - 10/2016
2Unstable Angina
01/2020 - 01/2019
2Hemorrhagic Stroke
11/2019 - 01/2019
2Pathologic Constriction (Stenosis)
01/2019 - 01/2018
1Mitral Valve Insufficiency (Mitral Regurgitation)
04/2024
1Left Ventricular Dysfunction
04/2024
1Liver Cirrhosis (Hepatic Cirrhosis)
11/2023
1Bites and Stings (Sting)
07/2022
1Hypersensitivity (Allergy)
07/2022
1Heart Failure
01/2021
1Inflammation (Inflammations)
01/2020
1Type 2 Diabetes Mellitus (MODY)
12/2019
1Intracranial Hemorrhages (Intracranial Hemorrhage)
11/2019
1Anemia
11/2019
1AIDS-Related Complex (ARC)
11/2019
1Diabetes Mellitus
04/2018
1Chronic Obstructive Pulmonary Disease (COPD)
09/2013
1Hypertension (High Blood Pressure)
09/2013
1Rupture
02/2010

Drug/Important Bio-Agent (IBA)

172'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
05/2024 - 07/2014
10Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2023 - 01/2012
9Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
05/2024 - 01/2015
6EverolimusFDA Link
05/2024 - 03/2017
6Clopidogrel (Plavix)FDA Link
10/2023 - 01/2019
5StreptokinaseFDA Link
01/2022 - 01/2018
5Tissue Plasminogen Activator (Alteplase)FDA Link
01/2022 - 01/2018
4BESIBA
08/2023 - 07/2013
4PolymersIBA
08/2023 - 03/2017
4Sirolimus (Rapamycin)FDA Link
01/2018 - 06/2012
4omega-Chloroacetophenone (Mace)IBA
12/2014 - 01/2011
3CobaltIBA
05/2024 - 01/2020
3N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA
05/2024 - 11/2023
3ChromiumIBA
05/2024 - 01/2020
3Serum AlbuminIBA
04/2024 - 12/2021
2Prasugrel HydrochlorideFDA Link
05/2024 - 11/2023
2pitavastatin (itavastatin)FDA Link
01/2023 - 01/2022
2Hemoglobins (Hemoglobin)IBA
01/2022 - 11/2019
2MetalsIBA
12/2015 - 04/2014
2thienopyridineIBA
11/2015 - 06/2012
1LDL CholesterolIBA
01/2023
1oxidized low density lipoproteinIBA
01/2023
1AlbuminsIBA
01/2022
1LipidsIBA
01/2022
1Insulin (Novolin)FDA Link
01/2020
1AngiopoietinsIBA
10/2016
1Coenzyme A (CoA)IBA
10/2016
1GlyceraldehydeIBA
10/2016
1Advanced Glycation End ProductsIBA
10/2016
1Dihydrotachysterol (AT 10)IBA
12/2015
1ThienopyridinesIBA
01/2015
1APTIBA
01/2015
1AnticoagulantsIBA
07/2014
1Angiotensin Receptor AntagonistsIBA
09/2013
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
09/2013
1Therapeutic UsesIBA
12/2012
1Ticlopidine (Ticlid)FDA LinkGeneric
06/2012

Therapy/Procedure

43Stents
05/2024 - 06/2012
36Percutaneous Coronary Intervention
01/2024 - 02/2010
25Therapeutics
05/2024 - 06/2012
19Drug-Eluting Stents
08/2023 - 11/2015
7Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2022 - 10/2012
1Polypharmacy
09/2023
1Duration of Therapy
04/2022
1Aftercare (After-Treatment)
01/2021
1Renal Dialysis (Hemodialysis)
01/2019
1Punctures
05/2012
1Cardiopulmonary Resuscitation (CPR)
02/2010